Insight

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah and Vania Hungria

Oct 26, 2024, 12:33

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, shared an article by Vania Hungria, Department of hematology at Santa Casa de São Paulo, on X:

” Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?”

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Authors: Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, D.Phil and Ana Carolina Ribas de Almeida

Al-Ola A Abdallah

Al-Ola A Abdallah Ana Carolina Ribas de Almeida cancer Christopher Ward combination therapy D.Phil Marek Hus Myeloma OncoDaily Oncology P. Joy Ho Pawel Robak Santa Casa de São Paulo University of Kansas Medical Center Vania Hungria Vera Zherebtsova

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC

Hesham ElGhazaly: Global Inclusion in Clinical Trials at Vision Europe 2025